Cancer Weekly articles from December 1992

Cancer Weekly archives from December 1992

Taxotere shows promise in first published trial in human patients. (University of Texas)
December 7, 1992... University of Texas The new drug Taxotere, like its relative Taxol, showed some evidence of activity against ovarian cancer and breast cancer in the first published initial (Phase I) study in humans, researchers reported in the December...

Taxol research may help in cancer fight. (University of Mississippi Research Institute of Pharmaceutical Sciences)
December 7, 1992... Mississippi Taxol has been called the most promising cancer drug in 15 years by the U.S. National Cancer Institute (NCI). The drug works by preventing cancer cells from multiplying. It has proven to be most effective in treating...

Grantees identify protein as tumor suppressor. (inhibin) (U.S. National Institute of Child Health and Human Development)
December 7, 1992... U.S. NICHD Researchers funded by the U.S. National Institute of Child Health and Human Development (NICHD) have determined that a reproductive hormone known as inhibin is directly involved in preventing the formation of certain...

Study estimates as many as 40 cases of hepatitis are prevented per day due to new blood screening test. (EIA-2) (American Association of Blood Banks)
December 7, 1992... American Association of Blood Banks As many as 40 cases of hepatitis are prevented per day since U.S. blood banks began using a second generation screening test for hepatitis C (HCV), according to research published in the...

Scientists report first demonstration that HMBA induces remission in some cancer patients. (hexamethylene bisacetamide; acute myelogenous leukemia) (Memorial Sloan-Kettering Cancer Center)
December 7, 1992... Memorial Sloan-Kettering Cancer Center Scientists at Memorial Sloan-Kettering Cancer Center, New York, New York, have reported the first demonstration that a new agent, HMBA (hexamethylene bisacetamide), can induce remission in patients...

Researchers set to begin brain tumor experiment. (injecting herpes virus genes, then treating with antiviral drug) (Iowa)
December 7, 1992... Iowa An experiment to attack brain tumors by changing their genetic makeup will likely get its first human tryout in December 1992. Dr. Kenneth Culver, an immunologist at the U.S. National Cancer Institute (NCI), said final safety...

Doctors say estrogen during menopause does not cause breast cancer. (Yale University)
December 7, 1992... Yale University Estrogen pills ease older women through the change of life and according to some doctors does not cause breast cancer. The medicine smooths out their hot flashes and mood swings. It keeps their hearts healthy and...

Governor Casey urges passage of mammography legislation. (Robert P. Casey) (Pennsylvania)
December 7, 1992... Pennsylvania Governor Robert P. Casey called for passage of legislation that would require health insurers to pay for biennial mammograms for women after the age of 40. The governor sent a letter urging members of the state House of...

Mammogram study shows patient control means less pain. (Duke University)
December 7, 1992... Duke University A study by Duke University, Durham, North Carolina, cancer researchers shows that giving women control over breast compression during a mammogram reduces the pain they feel, yet produces a satisfactory X-ray image. ...

New breast imaging breakthrough cleared for marketing. (LORAD DSM Digital Imaging System) (U.S. Food and Drug Administration)
December 7, 1992... U.S. FDA LORAD Corp., Danbury, Connecticut, a U.S. manufacturer of breast imaging and biopsy equipment, announced U.S. Food and Drug Administration (FDA) clearance to market the LORAD DSM Digital Imaging System. This technology...

Sylvester Center doctors embark on gene therapy for treatment of cancer. (Sylvester Comprehensive Cancer Center) (University of Miami)
December 7, 1992... University of Miami The University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, has been awarded an almost $3 million, four-year grant to study gene therapy as a treatment for cancer, announced Eckhard Podack, M.D.,...

Number of Skin Disease Research Core Centers doubles. (new centers at Yale University and the University of Texas Southwest Medical Center) (U.S. National Institute of Arthritis and Musculoskeletal and Skin Diseases)
December 7, 1992... U.S. NIAMS In a move that should significantly enhance the productivity of research on a host of skin disorders ranging from allergic reactions to skin cancer, the U.S. National Institute of Arthritis and Musculoskeletal and Skin...

Topical treatment for actinic keratoses introduced. (Actinex, masoprocol cream) (Reed & Carnrick Pharmaceuticals)
December 7, 1992... Reed & Carnrick Pharmaceuticals Reed & Carnrick Pharmaceuticals, Jersey City, New Jersey, announced the availability of Actinex (masoprocol cream), 10 percent for the treatment of actinic keratoses (AK), a common condition of skin damage...

Pittsburgh Cancer Institute receives support for new lung cancer program. (Pennsylvania)
December 7, 1992... Pennsylvania The Pittsburgh Cancer Institute (PCI) has received a $600,000, three-year grant from U.S. National Cancer Institute (NCI) to devise more effective strategies for preventing the development of lung cancer, identifying those...

Research professors named: $43 million in grants awarded. (Dr. Tony Hunter & Dr. Bert Vogelstein) (American Cancer Society)
December 7, 1992... American Cancer Society Two scientists who have made contributions in cancer research were recently named American Cancer Society Research Professors at the Society's Board of Directors meeting in November 1992. The Board also awarded...

Study marks 20 years of tracking radiation therapy progress. (Patterns of Care)
December 7, 1992... Patterns of Care The Patterns of Care Study, a nationwide evaluation of radiation oncology in the U.S., is celebrating its 20th anniversary. Patterns of Care is administered by the American College of Radiology and is funded by the...

Bionumerik Pharmaceuticals to use IBM technology in pursuit of accelerated drug development. (New York/Minnesota)
December 7, 1992... New York/Minnesota IBM, White Plains, New York, and BioNumerik Pharmacueticals Inc., Minneapolis, Minnesota, announced a joint effort dedicated to the development of parallel computing hardware and software for the design of a new...

Joint venture to market rhIL-11 in Japan. (recombinant human interleukin 11) (Massachusetts)
December 7, 1992... Massachusetts Genetics Institute Inc., Cambridge, Massachusetts, announced that it has licensed Japanese development and marketing rights for recombinant human interleukin 11 (rhIL-11) to GI-Yamanouchi Inc., its joint venture with...

Comprehensive European clinical trial program initiated. (monoclonal antibody-based diagnostic & therapeutic products) (Immunomedics Inc.)
December 7, 1992... Immunomedics Inc. Immunomedics Inc., Morris Plains, New Jersey, announced that it has initiated a comprehensive, advanced clinical trial program in Europe for its monoclonal antibody-based diagnostic and therapeutic products. Six...

Late small bowel complications in pelvic external beam postoperative radiotherapy: a clinical study of the volume factor. (Research Report)
December 7, 1992... AUTHORS: J.G.J. Letschert, J.V. Leberseque, B. Aleman, H. Bartelink, J.F. Bosset, J.C. Horiot, M. van Glabbeke and M. Pierart. EORTC Radiotherapy Cooperative Group, Amsterdam, the Netherlands. According to the authors' abstract of a...

Early S-phase delay by fluorodeoxyuridine (FdUrd) as a mechanism of fluoropyrimidine radiosensitization. (Research Report)
December 7, 1992... AUTHORS: Cornelius J. McGinn, Mary J. Lindstrom, John F. Fowler, Keith A. Kunugi and Timothy J. Kinsella. University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin. According to the authors' abstract of a poster...

Synergistic effects of taxol/taxotere on radiation sensitivity on human tumor cell lines. (Research Report)
December 7, 1992... AUTHORS: Hak Choy, Frank Rodriguez, Steve Leoster, Susan Hilsenbeck and Daniel D. Von Hoff. University of Texas Health Science Center, San Antonio, Texas. According to the authors' abstract of a poster presentation to the 34th Annual...

Interstitial pneumonitis following bone-marrow transplantation using fractionated low dose rate total body irradiation (TBI). (Research Report)
December 7, 1992... AUTHORS: Michael G. Chen, Louis Letendre, H. Clark Hoagland, Michelle M. Ryks and the Mayo Bone-Marrow Transplant Team. Mayo Clinic, Rochester, Minnesota. According to the authors' abstract of a poster presentation to the 34th Annual...

Iridium 192 template therapy in localized prostate cancer. (Research Report)
December 7, 1992... AUTHORS: Eashwer K. Reddy, Leela Krishnan, Winston Mebust and John Weigel. University of Kansas Medical Center, Kansas City, Kansas. According to the authors' abstract of a poster presentation to the 34th Annual Meeting of the American...

Potential underdosing with the use of electron beam therapy in patients with cervical adenopathy and advanced head and neck cancers. (Research Report)
December 7, 1992... AUTHORS: Susan A. Reisinger, Komandurin Ayyangar, Adam Flanders and Mohammed Mohiuddin. Thomas Jefferson University Hospital, Philadelphia, Pennsylvania. According to the authors' abstract of a poster presentation to the 34th Annual...

Phase I trial of taxotere: five-day schedule. (Periodical Report)
December 7, 1992... SOURCE: Journal of the National Cancer Institute, December 2, 1992;84(23):1781-1788. The semisynthetic Taxol relative Taxotere showed some evidence of activity against ovarian and breast cancer in a Phase I study reported by researchers...

Antitumor activity and clinical pharmacology of sulofenur in ovarian cancer. (Periodical Report)
December 7, 1992... SOURCE: Journal of the National Cancer Institute, December 2, 1992;84(23):1798-1802. The diarylsulfonylurea sulofenur exhibited modest clinical activity in a Phase II trial conducted by researchers at the Arizona Cancer Center. ...

Detection of human papillomavirus DNA in esophageal carcinoma in Japan by polymerase chain reaction. (Periodical Report)
December 7, 1992... SOURCE: Cancer, November 1, 1992;70(9):2234-2238. Most oncogenic types of human papilloma virus (HPV) can be detected by polymerase chain reaction in carcinoma of the esophagus, suggesting that HPV may play a role in this type of cancer....

Phase I and pharmacokinetic evaluation of all-trans-retinoic acid in pediatric patients with cancer. (Periodical Report)
December 7, 1992... SOURCE: Journal of Clinical Oncology, November, 1992;10(11):1666-1673. The maximum tolerated dosage and recommended Phase II dose for all-trans-retinoic acid (RA) in children with cancer is 60 mg/[m.sup.2]/d administered twice daily,...

Feasibility of using quinine, a potential multi-drug resistance-reversing agent, in combination with mitoxantrone and cytarabine for the treatment of acute leukemia. (Periodical Report)
December 7, 1992... SOURCE: Journal of Clinical Oncology, November, 1992;10(11):1730-1736. Quinine can be used safely as a potential reversing agent of multi-drug resistance for the treatment of clinically resistant acute leukemias, according to a report...

Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women. (Periodical Report)
December 7, 1992... SOURCE: Cancer Research, November 1, 1992;52:5933-5939. Exemestane appears to be less toxic than aminoglutethimide where the occurrence of clinically relevant toxicities is frequent, and further study of the agent is warranted in the...

New food labeling regulations announced. (U.S. Food and Drug Administration)
December 14, 1992... U.S. FDA U.S. Health and Human Services (HHS) Secretary Louis W. Sullivan, M.D., announced an agreement on final regulations which for the first time will provide for consistent, scientifically based labeling for nearly all processed...

Rules expediting availability of experimental drugs may take effect soon. (U.S. Food and Drug Administration)
December 14, 1992... U.S. FDA The U.S. Food and Drug Administration (FDA) will soon make more experimental drugs available quickly if they show promise of treating fatal or disabling diseases, the agency announced. The announcement means that the new...

Clinical practice guidelines help move pain management to front line of healthcare issues. (Agency for Health Care Policy and Research)
December 14, 1992... Agency for Health Care Policy and Research Response to the first set of clinical practice guidelines for the management of acute pain following surgery and other medical procedures has been met with great enthusiasm, according to the...

Study says low-level radiation poses cancer risk. (Hanford, Washington)
December 14, 1992... Washington A study of 35,000 workers at a U.S. nuclear complex concludes that people exposed to small doses of radiation are four to eight times more likely to contract cancer than previously estimated, according to a report published....

First human clinical trial of gene therapy to treat brain cancer initiated. (using herpes virus gene) (Genetic Therapy Inc.)
December 14, 1992... Genetic Therapy Inc. Genetic Therapy Inc. (GTI), Gaithersburg, Maryland, announced that it has, along with its U.S. National Institutes of Health (NIH) collaborators, initiated treatment of the first patient in the company's trial using...

Researchers discover link between G-proteins and cell growth. (State University of New York, Stonybrook)
December 14, 1992... State University of New York, Stonybrook Researchers at the University at Stony Brook Health Sciences Center, Stonybrook, New York, have found that a certain class of proteins, termed G*proteins, may play a fundamental role in regulating...

New method to treat prostate cancer shows promise. (percutaneous ultrasound-guided prostate cryosurgery) (Allegheny General Hospital, Pittsburgh, Pennsylvania)
December 14, 1992... Pennsylvania Preliminary results of a 94-patient study at Allegheny General Hospital (AGH), Pittsburgh, Pennsylvania, suggest that a minimally invasive surgical procedure known as Percutaneous Ultrasound-guided Prostate Cryosurgery may...

Smart antibody shows activity and no immunogenicity in Phase I trial. (Smart Anti-Tac Antibody) (Protein Design Labs Inc.)
December 14, 1992... Protein Design Labs Protein Design Labs (PDL), Mountain View, California, announced that its Smart Anti-Tac Antibody did not elicit a human anti-mouse antibody (HAMA) response in any of the patients who received the drug in a Phase I...

Chronic hepatitis C trials initiated using injectable natural-source alpha interferon. (Interferon Sciences Inc.)
December 14, 1992... Interferon Sciences Inc. Interferon Sciences Inc., New Brunswick, New Jersey, announced the commencement of a clinical trial utilizing its injectable formulation of interferon alfa-n3 (human leukocyte derived). This multicenter,...

IND on therapeutic vaccine for chronic hepatitis B infection filed. (Investigational New Drug application; CY1899) (Cytel Corporation)
December 14, 1992... Cytel Corporation Cytel Corporation, San Diego, California, announced that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) on behalf of Sequel Therapeutics, Cytel's joint...

Results of basal cell cancer Phase II clinical trial presented. (MPI 5003 Fluorouracil Therapeutic Implant) (Matrix Pharmaceutical Inc.)
December 14, 1992... Matrix Pharmaceutical Inc. Matrix Pharmaceutical Inc., Menlo Park, California, reported Phase II clinical trial results of its lead product candidate, MPI 5003 Fluorouracil Therapeutic Implant, noting significant levels of efficacy for...

Company targets three types of lymphoma for IL-2 Fusion Toxin trials. (Seragen Inc.)
December 14, 1992... Seragen Inc. Seragen Inc., Hopkington, Massachusetts, investigators have determined that three types of lymphoma patients appear to have the highest percentage of IL-2 receptor expression on their malignant cells and, therefore, the...

New video assists people recovering from cancer. ("Getting on With It") (Centocor Inc.)
December 14, 1992... Centocor Inc. A new videotape for persons recovering from cancer has just been released. The videotape is described as a video "handbook" of practical advice and guidance from 12 women who have had cancer themselves. "Getting...

Possible loss of heterozygosity in centric fusion 1;7 associated with myelodysplastic syndrome and acute non-lymphocytic leukemia. (Research Report)
December 14, 1992... AUTHORS: S.A. Tharpel. University of Tennessee, Memphis, Tennessee. According to the author's abstract of a poster presentation to the 42nd Annual Meeting of the American Society of Human Genetics, held in San Francisco, California,...

Characterization of a rearranged chromosome 11 by chromosome in situ suppression hybridization (CISS) in case of acute myeloblastic leukemia (AML-M2). (Research Report)
December 14, 1992... AUTHORS: R.T. Silver, M.J. Macera and R.S. Verma. The New York Hospital-Cornell Medical Center, New York, New York. According to the abstract of a poster presentation to the 42nd Annual Meeting of the American Society of Human Genetics,...

Molecular diagnosis of the Philadelphia chromosome in patients with unconfirmed chronic myelogenous leukemia (CML). (Research Report )
December 14, 1992... AUTHORS: J. Paulus-Thomas, A. Zahorchak and J. Miklos. West Penn Hospital, Pittsburgh, Pennsylvania. According to the authors' abstract of a poster presentation to the 42nd Annual Meeting of the American Society of Human Genetics, held...

3q26: a most frequent breakpoint in acute myelogenous leukemia (AML-M2). (Research Report)
December 14, 1992... AUTHORS: S.K. Gogineni, M. da Costa, G. Palermo and R.S. Verma. The Long Island College Hospital-State University of New York Health Science Center at Brooklyn, New York. According to the author's abstract of a poster presentation to...

What is the true incidence of complex 15;17 translocations in acute promyelocytic leukemia? (Research Report)
December 14, 1992... AUTHORS: M.L. Slovak. City of Hope National Medical Center, Duarte, California. According to the author's abstract of a poster presentation to the 42nd Annual Meeting of the American Society of Human Genetics, held in San Francisco,...

Bilateral glomus body tumors in a patient with Rothmund-Thomson syndrome. (Research Report)
December 14, 1992... AUTHORS: M.B. Dinulos and J. Mulvilhill. Eastern Virginia Medical School, Norfolk, Virginia. According to the authors' abstract of a poster presentation to the 42nd Annual Meeting of the American Society of Human Genetics, held in San...

Non-Hodgkin lymphoma: familial clustering with immunodeficiency is suggestive of genetic susceptibility to lymphoid malignancy. (Research Report)
December 14, 1992... AUTHORS: O. Ginsburg, E. Treacy, C. Shustik and S. Narod. McGill University, Montreal, Canada. According to the authors' abstract of a poster presentation to the 42nd Annual Meeting of the American Society of Human Genetics, held in...

Cytogenetic analysis of eight cases of primary osteosarcoma. (Research Report)
December 14, 1992... AUTHORS: W.A. Hoogerwerf, A.L. Hawkins, E. Periman and C.A. Griffin. The Johns Hopkins School of Medicine, Baltimore, Maryland. According to the authors' abstract of a poster presentation to the 42nd Annual Meeting of the American...

Kaposi's sarcoma as sexually transmissible infection. (Research Report)
December 14, 1992... AUTHORS: J. Elford, A. McDonald and J. Kaldor. National HIV Surveillance Committee, National Centre in HIV Epidemiology and Clinical Research, New South Wales, Australia. According to an abstract presented at the 5th National Conference...

Thallium scanning in the diagnosis of Kaposi's sarcoma. (Research Report)
December 14, 1992... AUTHORS: Y. Singh, I. Gosbell, W. Fong, D. Goldstein, W. Handl and P. Jones. Prince Henry Hospital, Anzac Parade, Little Bay, Australia. According to an abstract presented at the 5th National Conference on AIDS, held in Sydney,...

Retinoic acids inhibit AIDS-Kaposi's sarcoma tumor cell growth in vitro and in vivo. (Research Report)
December 14, 1992... AUTHORS: J. Cai, R. Masood, G. Lin, B.M. Espina, R. Law, B. Aggarwahl and P.S. Gill. University of Southern California School of Medicine, Los Angeles, California; M.D. Anderson Hospital, Houston, Texas. According to an abstract...

AIDS-KS derived cultured spindle cells induce vascular hyper-permeability which may be the cause of edema in patients with Kaposi's sarcoma. (Research Report)
December 14, 1992... AUTHORS: S. Nakamura, S. Sakurada, H.A. Weich, S. Rasheed and S.Z. Salahuddin. Institute of Molecular Medicine & Technology, Huntington Memorial Hospital, Pasadena, California; and Department of Medicine, University of Southern California...

California consortium treatment group trial of ABV followed by maintenance therapy with interferon-alpha and ZDV in HIV-associated Kaposi's sarcoma. (adriamycin, bleomycin, vincristine; zidovudine) (Research Report)
December 14, 1992... AUTHORS: E. Feigal, A. Levine, E. Muchmore, L. Slater, B. Espina, A. McCutchan and P. Gill. University of California, San Diego, California (UCSD); University of Southern California, Los Angeles, California (USC); University of California,...

Liposomal daunorubicin (DaunoXome), an effective agent in the treatment of advanced AIDS-related Kaposi's sarcoma. (Research Report)
December 14, 1992... AUTHORS: P.S. Gill, B.M. Espina, S. Cabriales, M. Ross, R. Crossley, F. Muggia and A.M. Levine. University of Southern California School of Medicine, Los Angeles, California; Vestar Corporation, San Dimas, California. According to an...

Role of steroid hormones in AIDS-Kaposi's sarcoma. (Research Report)
December 14, 1992... AUTHORS: R. Law, R. Masood, G. Lin, B. Jung, J. Cai and P.S. Gill. University of Southern California School of Medicine, Los Angeles, California. According to the authors' abstract submitted to the Thirty-Fourth Annual Meeting of the...

Low dose m-BACOD with concomitant dideoxycytidine (ddC) in AIDS-related lymphoma. (bleomycin, adriamycin, cytoxan, decadron) (Research Report)
December 14, 1992... AUTHORS: A.M. Levine, E. Katz-Willson, B. Espina, J. Esplin, A. Ortega, S. Rasheed, B. Nathwani and P.S. Gill. University of Southern California School of Medicine, Los Angeles, California. According to an abstract presented to the...

Host-specific interleukin-2-secreting donor T-cell precursors as predictors of acute graft-versus-host disease in bone-marrow transplantation between HLA-identical siblings. (Periodical Report)
December 14, 1992... SOURCE: The New England Journal of Medicine, December 3, 1992;327(23):1613-1617. Analysis of the frequency of host-specific interleukin-2-secreting donor T-cell precursors in HLA-identical subjects undergoing allogeneic bone-marrow...

Breast cancer screening among women from 65 to 74 years of age in 1987-88 and 1991. (Periodical Report)
December 14, 1992... SOURCE: Annals of Internal Medicine, December 1, 1992;117(11):961-966. More elderly women than ever are getting mammograms, but the use of clinical breast examination may be decreasing among this population, according to a report from...

Increase of cyclophosphamide on long-term reduction in sperm count in men treated with combination chemotherapy for Ewing and soft tissue sarcomas. (Periodical Report)
December 14, 1992... SOURCE: Cancer, December 1, 1992;70(11):2703-2712. A risk of permanent sterility is associated with the use of cyclophosphamide, doxorubicin and dacarbazine (CYADIC) and the same regimen with vincristine (CYVADIC) in young men treated...

A meta-analysis of thoracic radiotherapy for small-cell lung cancer. (Periodical Report)
December 14, 1992... SOURCE: New England Journal of Medicine, December 3, 1992;327(23):1618-1624. Thoracic radiotherapy moderately improves survival in patients with limited small-cell lung cancer who are treated with combination chemotherapy, but...

White matter changes in children treated for acute lymphoblastic leukemia. (central nervous system therapy) (Periodical Report)
December 14, 1992... SOURCE: Cancer, December 1, 1992;70(11):2728-2733. Magnetic resonance (MR) imaging is a sensitive detector of white matter changes in children with acute lymphoblastic leukemia, but its value during follow-up remains to be determined,...

New directive on device used for treating cancer patients. (Omnitron Model 2000 High Dose Rate Afterloader) (U.S. Nuclear Regulatory Commission)
December 21, 1992... DATELINE: U.S. NRC The U.S. Nuclear Regulatory Commission (NRC) has sent a directive to all NRC licensees authorized to use a specific device (Omnitron Model 2000 High Dose Rate Afterloader) used for treating patients suffering from...

Agency admits fumbling investigation. (of deaths due to radiation overdose) (U.S. Nuclear Regulatory Commission)
December 21, 1992... DATELINE: U.S. NRC A U.S. Nuclear Regulatory Commission (NRC) spokesman admitted that the agency "did not do a thorough follow-up" when an Ohio hospital gave radiation overdoses to hundreds of cancer patients. The Cleveland Plain...

Taxol production expanded. (ESCAgenetics Corp.)
December 21, 1992... DATELINE: ESCAgenetics ESCAgenetics Corp., San Carlos, California, announced that it has expanded its Taxol development and discovery programs to accommodate a broad spectrum of anticipated supply needs for Taxol and semisynthetic forms...

Prostate cancer prevention trial begins. (4HPR, a vitamin A-like drug) (Michigan)
December 21, 1992... DATELINE: Michigan Researchers at Harper Hospital/Wayne State University, Detroit, Michigan, have begun the first clinical trial in the world using a vitamin A-like drug aimed at preventing prostate cancer in high-risk individuals. ...

Companies find mammography machine pays for itself. (Illinois)
December 21, 1992... DATELINE: Illinois Some U.S. corporations are finding that maintaining company mammography machines for use by female employees has a positive effect on their bottom line. One cancer survivor says her employer, ICI Americas Inc.,...

Researchers focus on cancer prevention. (Washington State University)
December 21, 1992... DATELINE: Washington State University There are hundreds of complicated biological and environmental causes for cancer, but a team of Washington State University, Pullman, Washington, researchers is looking for a few simple ways to...

Cancer specialist develops comprehensive cancer screening test. (Ronald S. Scott; CancerQuest Risk Assessment) (California)
December 21, 1992... DATELINE: California Nearly one million people will be diagnosed with cancer in 1992, and more than 500,000 people will die of the disease. Despite treatment advances, these statistics persist because doctors diagnose most cancers...

Results of Phase I/II clinical trial reported. (recombinant human thyroid stimulating hormone) (Genzyme Corp.)
December 21, 1992... DATELINE: Genzyme Corporation Results from the Phase I/II clinical study of recombinant human thyroid stimulating hormone (rhTSH) were presented by investigators at the Annual American Thyroid Association Conference in Rochester,...

Blood test may provide early diagnosis for cancer. (test for a tumor-associated antigen developed by Donald L. Morton) (California)
December 21, 1992... DATELINE: California The Transamerica Insurance Co. of Los Angeles, California, has announced that it will offer life insurance to anyone testing negative on a tumor marker blood test developed by Dr. Donald L. Morton. Morton is medical...

New test finds defects in p53 gene faster. (Massachusetts)
December 21, 1992... DATELINE: Massachusetts A new test appears to greatly speed up the painstaking process of finding people at high risk of cancer because they inherit bad copies of a gene that ordinarily holds the disease in check, a researcher said. ...

Results of public survey on human genetics released. (March of Dimes)
December 21, 1992... DATELINE: March of Dimes The nation's first public opinion survey on human genetics has found that the vast majority of Americans support the use of gene therapy to treat disease and favor continuing genetic research. The poll also...

Researchers report advances in cell and gene therapy. (Washington)
December 21, 1992... DATELINE: Washington CellPro, Bothell, Washington, reported highlights of the recent CellPro-sponsored symposium Stem Cells: From Selection Through Expansion, A Look at Therapeutic Applications. At the symposium, researchers...

Medical center announces first human gene therapy institute. (University of Pennsylvania)
December 21, 1992... DATELINE: University of Pennsylvania William N. Kelley, M.D., chief executive officer of the University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, and dean of the School of Medicine, announced the formation of the...

NIH grant awarded to new center for gene therapy. (National Institutes of Health) (California)
December 21, 1992... DATELINE: California The City of Hope National Medical Center and Beckman Research Institute, Duarte, California, announced the creation of a new center for basic research and clinical implementation of gene therapy and the receipt of a...

$4 million awarded for the development of genetic therapy for cancer. (Indiana University)
December 21, 1992... DATELINE: Indiana University Researchers at the Indiana University (I.U.) School of Medicine, Bloomington, Indiana, have been awarded $4 million in funding over the next four years by the U.S. National Cancer Institute (NCI) of the U.S....

Genentech receives U.S. nerve growth factor patent. (California)
December 21, 1992... DATELINE: California Genentech Inc., South San Francisco, California, announced that it has been issued a U.S. patent relating to human nerve growth factor (NGF) made by recombinant DNA technology. The patent covers nucleic acids,...

Researcher says breast implants may be linked to autoimmune diseases. (Henry Claman) (University of Colorado)
December 21, 1992... DATELINE: University of Colorado Breast implants may be linked with the development of auto-immune diseases but there is no proof as yet, according to preliminary results by a University of Colorado (UC), Boulder, Colorado, researcher....

National Cancer Institute briefing on 'Therapeutic Studies of Primary Central Nervous System Malignancies in Adults.' (Research Report)
December 21, 1992... AUTHORS: National Cancer Institute. "Request for Applications (RFA) CA-93-03, for cooperative agreements (U01) from consortia of institutions to perform Phase I and II clinical evaluations of promising new chemotherapeutic or biologic...

Management and operation of the NCI Frederick Cancer Research and Development Center. (National Cancer Institute) (Research Report)
December 21, 1992... AUTHORS: National Cancer Institute. "The National Cancer Institute (NCI) is seeking sources to perform research, operation and technical support, animal production, computer services and scientific library services at the NCI Frederick...